Co-agonist therapeutics come of age for obesity

Glucagon-like peptide 1 (GLP1) analogues are licensed options for obesity, but new treatments are required to obtain better weight loss and to directly address other co-morbidities, such as non-alcoholic fatty liver disease. Research published in 2022 shows that co-agonist combinations of GLP1 with other hormones provide clinically important advances.

Automated summary

GLP1 analogues are approved treatments for obesity, but novel therapies are needed for improved weight loss and the direct treatment of other comorbidities, such as non-alcoholic fatty liver disease. Recent research published in 2022 demonstrates that co-agonist combinations of GLP1 with other hormones offer clinically significant advancements.